XML 242 R62.htm IDEA: XBRL DOCUMENT
v3.22.4

Other Disclosures - Collaborations and Technology Licenses (Details) kr in Millions, $ in Millions |  |  | 1 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
Jun. 09, 2022 USD ($) | Jun. 10, 2020 DKK (kr) item product | Jun. 10, 2020 USD ($) item product | Sep. 30, 2021 | Oct. 31, 2020 | Jun. 30, 2020 DKK (kr) | Jun. 30, 2020 USD ($) | Dec. 31, 2022 USD ($) item Option | Dec. 31, 2021 USD ($) | Dec. 31, 2012 | Dec. 31, 2022 DKK (kr) product | Dec. 31, 2022 USD ($) product | Dec. 31, 2021 DKK (kr)
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Investments accounted for using equity method | kr |  |  |  |  |  |  |  |  |  |  | kr 133 |  | kr 371
Janssen |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty obligation expiration term after first sale of product |  |  |  |  |  |  |  | 13 years |  |  |  |  |
Amount of seeking an award | $ 405.0 |  |  |  |  |  |  |  |  |  |  |  |
New royalty term entitled as mentioned in declaration | 13 years |  |  |  |  |  |  |  |  |  |  |  |
Janssen (DuoBody) |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments receivable |  |  |  |  |  |  |  |  |  |  |  | $ 191.0 |
Upfront payment |  |  |  |  |  |  |  | $ 3.5 |  |  |  |  |
Number of additional programs | item |  |  |  |  |  |  |  | 10 |  |  |  |  |
Initial payments received |  |  |  |  |  |  |  | $ 2.0 |  |  |  |  |
Number of license exercised | item |  |  |  |  |  |  |  | 14 |  |  |  |  |
Number of license options remaining to be exercised | Option |  |  |  |  |  |  |  | 0 |  |  |  |  |
Number of products were in active clinical development | product |  |  |  |  |  |  |  |  |  |  | 3 | 3 |
Royalties expiration term after the first sale of each licensed product |  |  |  |  |  |  |  | 10 years |  |  |  |  |
Novartis (Arzaerra/Ofatumumab) |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percentage for non-cancer treatment |  |  |  |  |  |  |  | 10.00% |  |  |  |  |
Lump sum payment received |  |  |  |  |  |  |  |  | $ 30.0 |  |  |  |
Seagen |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Cost and profit sharing ratio |  |  |  |  | 50 |  |  |  |  |  |  |  |
Profits sharing percentage |  |  |  | 50.00% |  |  |  |  |  |  |  |  |
AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  | kr 4,911 | $ 750.0 |  |  |  |  |  |
Ratio of share of profits before income taxes |  |  | 50 |  |  |  |  |  |  |  |  |  |
Ratio of sharing pre tax profits |  | 50 | 50 |  |  |  |  |  |  |  |  |  |
Number of performance obligations | item |  | 4 | 4 |  |  |  |  |  |  |  |  |  |
Number of delivery license programs | item |  |  | 3 |  |  |  |  |  |  |  |  |  |
Percentage of discover research and development cost responsible by the entity |  | 100.00% | 100.00% |  |  |  |  |  |  |  |  |  |
Maximum number of product concepts for which cost-plus margin approach was utilized | product |  | 4 | 4 |  |  |  |  |  |  |  |  |  |
Contract Transaction Price |  | kr 4,911 | $ 750.0 |  |  |  |  |  |  |  |  |  |
Notice period for solely responsible for further development of product |  |  |  | 180 days |  |  |  |  |  |  |  |  |
BioNTech |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront fee paid |  |  |  |  |  |  |  | $ 10.0 |  |  |  |  |
Number of investigational medicines currently in clinical development | item |  |  |  |  |  |  |  | 4 |  |  |  |  |
Performance obligations satisfied at point in time | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Contract Transaction Price |  | 4,398 | 672.0 |  |  |  |  |  |  |  |  |  |
Performance obligations satisfied over time | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Contract Transaction Price |  | kr 513 | $ 78.0 |  |  |  |  |  |  |  |  |  |
Bottom of range [member] | Janssen |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalty percentage |  |  |  |  |  |  |  |  |  | 12.00% |  |  |
Bottom of range [member] | Janssen (DuoBody) |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of royalties |  |  |  |  |  |  |  | 8.00% |  |  |  |  |
Bottom of range [member] | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalty percentage |  | 22.00% | 22.00% |  |  |  |  |  |  |  |  |  |
Top of range [member] | Janssen |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalty percentage |  |  |  |  |  |  |  |  |  | 20.00% |  |  |
Top of range [member] | Janssen (DuoBody) |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments receivable |  |  |  |  |  |  |  |  |  |  |  | $ 175.0 |
Percentage of royalties |  |  |  |  |  |  |  | 10.00% |  |  |  |  |
Top of range [member] | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalty percentage |  | 26.00% | 26.00% |  |  |  |  |  |  |  |  |  |
Contractually entitled to receive amount in additional development, regulatory and sales milestone payments |  |  | $ 2,550.0 |  |  |  |  |  |  |  |  |  |
Contractually entitled to receive payments related to clinical development and commercial success |  |  | 550.0 |  |  |  |  |  |  |  |  |  |
Development Regulatory and Sales Milestone | Top of range [member] | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Receivables |  |  | 3,150.0 |  |  |  |  |  |  |  |  |  |
Clinical Development and Commercial Success Across all Three Programs | Development Regulatory and Sales Milestone | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Receivables |  |  | 1,150.0 |  |  |  |  |  |  |  |  |  |
Success of all Four Next Generation Antibody Product Candidates Developed | Development Regulatory and Sales Milestone | AbbVie |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations and Technology Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Receivables |  |  | $ 2,000.0 |  |  |  |  |  |  |  |  |  |

X
- Definition Represents the amount of seeking an award in this second arbitration. + References No definition available. + Details
Name: | gmab_AmountOfSeekingAwardInSecondArbitration
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of profits sharing for the product of Tivdak. + References No definition available. + Details
Name: | gmab_CollaborationAgreementProfitsSharingPercentage
Namespace Prefix: | gmab_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the cost and profit sharing ratio. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementCostAndProfitSharingRatio
Namespace Prefix: | gmab_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash in flow from initial payments received. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementInitialPaymentReceived
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payment receivable under an collaboration agreement. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementMilestonePaymentReceivable
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of royalties of worldwide net sales ofatumumab for the treatment of non-cancer under the agreement. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementNonCancerTreatmentRoyaltyPercentageOnWorldWideNetSales
Namespace Prefix: | gmab_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of lump sum payment received under an collaboration agreement for lost potential royalties. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementPaymentReceivedForLostRoyalties
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the royalties expiration term after the first sale of each licensed product in such country. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementRoyaltiesExpirationTermAfterFirstSaleOfEachLicensedProduct
Namespace Prefix: | gmab_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of royalties under collaboration agreement. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementRoyaltiesPercentage
Namespace Prefix: | gmab_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term from first sale of the product after which obligation to pay royalties under the agreement will expire. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementRoyaltyObligationExpirationTermAfterFirstSaleOfProduct
Namespace Prefix: | gmab_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of tiered royalty under the collaboration agreement. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementTieredRoyaltyPercentage
Namespace Prefix: | gmab_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront fee payment made under an collaboration agreement. + References No definition available. + Details
Name: | gmab_CollaborationsAgreementUpfrontFeePaid
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The identified transaction price under the contract. + References No definition available. + Details
Name: | gmab_ContractTransactionPrice
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of discover research and development cost responsible by the entity. + References No definition available. + Details
Name: | gmab_DiscoverResearchAndDevelopmentCostResponsibilityPercent
Namespace Prefix: | gmab_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the maximum number of product concepts for which a cost-plus margin approach was utilized for co-development activities. + References No definition available. + Details
Name: | gmab_MaximumNumberOfProductConceptsForWhichCostPlusMarginApproachWasUtilized
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the new royalty term entitled from the date of DARZALEX FASPRO's first commercial sale as mentioned in declaration in second arbitration. + References No definition available. + Details
Name: | gmab_NewRoyaltyObligationTermFromDateOfFirstCommercialSaleOfProduct
Namespace Prefix: | gmab_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The notice period after which company is solely responsible for the further development of DuoHexaBody-CD37. + References No definition available. + Details
Name: | gmab_NoticePeriodForSolelyResponsibleForFurtherDevelopmentOfProduct
Namespace Prefix: | gmab_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of additional programs party to the agreement is entitled to work on. + References No definition available. + Details
Name: | gmab_NumberOfAdditionalProgramEntitledToBeWorked
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of delivery license programs. + References No definition available. + Details
Name: | gmab_NumberOfDeliveryLicenses
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the number of investigational medicines currently in clinical development. + References No definition available. + Details
Name: | gmab_NumberOfInvestigationalMedicinesCurrentlyInClinicalDevelopment
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of license exercised under the agreement. + References No definition available. + Details
Name: | gmab_NumberOfLicenseOptionsExercised
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of license options remaining to be exercised under the agreement. + References No definition available. + Details
Name: | gmab_NumberOfOptionsRemainingToBeExercised
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of performance obligations. + References No definition available. + Details
Name: | gmab_NumberOfPerformanceObligations
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of DuoBody-based products created under this collaboration were in active clinical development. + References No definition available. + Details
Name: | gmab_NumberOfProductsWereInActiveClinicalDevelopment
Namespace Prefix: | gmab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The ratio of share of profits before income taxes. + References No definition available. + Details
Name: | gmab_RatioOfShareOfProfitsBeforeIncomeTaxes
Namespace Prefix: | gmab_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition The ratio of sharing pre tax profits during the period. + References No definition available. + Details
Name: | gmab_RatioOfSharingPreTaxProfits
Namespace Prefix: | gmab_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the contractually entitled to receive an aggregate payment, related to additional development, regulatory and sales milestone payments for all programs. + References No definition available. + Details
Name: | gmab_ReceivableAmountRelatedToAdditionalDevelopmentRegulatoryAndSalesMilestonePayments
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the contractually entitled to receive payments related to clinical development and commercial success. + References No definition available. + Details
Name: | gmab_ReceivableAmountRelatedToClinicalDevelopmentAndCommercialSuccess
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Na + References No definition available. + Details
Name: | gmab_ShareholdingsByBoardOfDirectorsAndExecutiveManagementLineItems
Namespace Prefix: | gmab_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash in flow from upfront milestone payments. + References No definition available. + Details
Name: | gmab_UpfrontMilestonePaymentReceived
Namespace Prefix: | gmab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2022-03-24 -Paragraph 24 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard -URIDate 2022-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 54 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_e&doctype=Standard -URIDate 2022-03-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2022-03-24 -Paragraph B16 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B16&doctype=Appendix&subtype=B -URIDate 2022-03-24 + Details
Name: | ifrs-full_InvestmentAccountedForUsingEquityMethod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 54 -Subparagraph h -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_h&doctype=Standard -URIDate 2022-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 78 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_TradeAndOtherReceivables
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithJanssenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementWithJanssenDuobodyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithNovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithSeagenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithBointechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedAtPointInTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_PerformanceObligationsAxis=ifrs-full_PerformanceObligationsSatisfiedOverTimeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | gmab_TypesOfRevenuesAxis=gmab_DevelopmentRegulatoryAndSalesMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=gmab_ClinicalDevelopmentAndCommercialSuccessAcrossAllThreeProgramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=gmab_SuccessOfAllFourNextGenerationAntibodyProductCandidatesDevelopedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |